Beam Therapeutics Inc. pivots from platform story to execution-driven thesis, with regulatory clarity accelerating BEAM-302 ...

Beam stock launched Monday after the company reached a deal with the Food and Drug Administration for its gene-editing drug, ...

Futuristic 3D cubes showing DNA base pairs and a double helix. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive ...

Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency ...

Beam Therapeutics focuses on base editing technology, which allows for precise changes at the DNA level and potentially reduces off-target effects. Base editing has the versatility to correct a wide ...

Beam Therapeutics BEAM is engaged in developing investigational gene therapy candidates that are currently in early-to-mid-stage development for treating certain hematology and genetic diseases. The ...

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Beam Therapeutics Inc. (NASDAQ:BEAM) stands ...

Beam Therapeutics’ experimental gene-editing therapy for sickle cell disease now has its first cut of patient data showing signs of treating the rare blood disorder in a way that could differentiate ...

A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has early signs of efficacy along with safety data that ease some concerns about ...

On Monday, Beam Therapeutics Inc. (NASDAQ:BEAM) announced initial safety and efficacy data from its Phase 1/2 trial of BEAM-302, establishing clinical proof-of-concept as a potential treatment for ...

NEW YORK and CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE: PFE) and Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines ...